Blocking CTGF-Mediated Tumor-Stroma Interplay in Pancreatic Cancer

Area of Science:

• Oncology
• Cancer Biology
• Fibrosis Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma, which impedes therapeutic efficacy.
• This fibrotic microenvironment is a major challenge in PDAC treatment.
• Emerging evidence implicates connective tissue growth factor (CTGF) in promoting this fibrotic reaction.

Purpose of the Study:

• To investigate the role of connective tissue growth factor (CTGF) in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
• To evaluate CTGF as a potential therapeutic target for overcoming treatment resistance in PDAC.

Main Methods:

• Analysis of PDAC tissue samples to assess CTGF expression levels.
• In vitro studies using PDAC cell lines to examine the effects of CTGF on stromal components.
• In vivo models to evaluate the impact of targeting CTGF on tumor growth and fibrosis.

Main Results:

• Elevated CTGF levels were observed in PDAC tissues, correlating with increased stromal density.
• CTGF was found to stimulate the production of extracellular matrix proteins by cancer-associated fibroblasts.
• Inhibition of CTGF led to reduced tumor progression and desmoplasia in preclinical models.

Conclusions:

• Connective tissue growth factor (CTGF) plays a critical role in promoting the desmoplastic stroma in PDAC.
• Targeting CTGF presents a promising therapeutic avenue to enhance treatment outcomes for pancreatic cancer.